{"slug":"vip-tendon","verification":{"valid":true,"entries":1,"head":"5c5ceab305c936667a0ef5c1a7ab7a36ad470b94aff2182160db223f8c7430bb"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.023819,"waste_cost_usd":0,"total_tokens":16977,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.023819,"tokens_total":16977,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T22:15:44.722Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"VIP for Tendon Repair: What the Data Shows","register":"source_ledger","body":"## What's breaking down\n\nTendon tissue has limited natural repair capacity. Degeneration often involves chronic low-grade inflammation, disrupted immune balance with excess M1 macrophages, reduced function of tendon stem/progenitor cells (TSPCs), and poor organized collagen deposition. If breakdown outruns repair, tendinopathy persists. VIP is discussed here for its studied effects on immune modulation and tissue repair pathways rather than symptom suppression.\n\n## Why VIP might help you\n\nIf immune imbalance or poor macrophage polarization contributes to your tendon issue, VIP is examined because it targets repair mechanisms at the tissue level. In one line of research, VIP promoted M2 macrophage polarization, which supports resolution of inflammation and tissue remodeling instead of prolonged pro-inflammatory states. If TSPC function is impaired, the same work showed VIP helped maintain those cells' activity during regeneration. Therefore for you: if that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.\n\n## How these fit together\n\nSingle-compound focus. VIP addresses the immune/autonomic layer through modulation of inflammatory homeostasis and support for progenitor cell function in tendon models.\n\n## What the evidence actually shows\n\nA 2025 preclinical study (Wang et al.) implanted VIP-loaded nanoparticles (VPZG) at patellar tendon injury sites in Sprague-Dawley rats. VIP release promoted tendon regeneration by shifting macrophages toward M2 phenotype, regulating immune balance, and preserving TSPC function. This was an animal model with localized sustained delivery; it demonstrates mechanistic effects in rats but does not prove outcomes in humans. (source s1)\n\nEarlier animal work (Delgado et al., 2001) showed VIP reduced incidence and severity of collagen-induced arthritis in mice, with less inflammatory infiltrate and joint destruction. This is preclinical evidence of immunomodulation in an inflammatory joint model, not a tendon-specific study. (source s2)\n\nNo randomized controlled human trials for VIP in tendon healing were identified. Human data on VIP remain limited to other contexts such as migraine provocation or pulmonary effects.\n\n## What scientists say\n\nResearchers note VIP's role in immune homeostasis and its potential in regenerative settings via macrophage polarization and progenitor cell support, based on the rat tendon nanoparticle model. Broader reviews highlight VIP's anti-inflammatory actions in animal arthritis models but call for more translational work. Human applicability to tendon repair is described as untested in clinical trials.\n\n## What people say on Reddit\n\nDiscussions of VIP on peptide forums focus on general immunomodulation, gut motility, or respiratory effects. Specific tendon repair anecdotes tied to VIP are absent in available threads; users more commonly reference other peptides for soft tissue topics.\n\n## What people say on X\n\nPublic posts referencing VIP and tendons are not prominent. General mentions of VIP center on its endogenous roles in vasodilation or inflammation balance without tendon-specific user reports.\n\n## What we do not know\n\nLong-term human safety and efficacy data for tendon applications are absent. Optimal delivery methods, dosing schedules, and whether systemic versus localized VIP affects tendon outcomes remain unknown. Translation from rat nanoparticle models to human tendinopathy has not been studied.\n\n## Safety and limits\n\nVIP research in tendon contexts is preclinical only. Any use carries unknown risks due to lack of human tendon trials. Regulatory status and manufacturing standards for research compounds apply; consult qualified professionals for personal health decisions.","claims":[{"id":"c1","text":"2025 rat study showed VIP nanoparticles promoted patellar tendon regeneration via M2 macrophage shift and TSPC support","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s1"],"source_status":"sourced","why_material":"Only direct tendon-specific data; establishes immune/tissue repair layer","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:15:43.821Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"2001 mouse arthritis study found VIP reduced joint inflammation and destruction","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s2"],"source_status":"sourced","why_material":"Supports immunomodulatory mechanism relevant to chronic tendon inflammation","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:15:43.821Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"No human clinical trials exist for VIP in tendon repair","section":"What the evidence actually shows","tier":"human","source_ids":[],"source_status":"unsourced","why_material":"Clarifies evidence gap for readers","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T22:15:43.821Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40184556/","title":"Nanoparticle-Driven Tendon Repair: Role of Vasoactive Intestinal Peptide in Immune Modulation and Stem Cell Enhancement","quote":"Our results demonstrated that VPZG facilitated tendon injury repair by regulating immune homeostasis and enhancing TSPC function.","link_status":"ok","quote_status":"verified"},{"id":"s2","type":"pubmed","url":"https://www.hopkinsarthritis.org/arthritis-news/vasoactive-intestinal-peptide-vip-prevents-experimental-arthritis-news-summary-from-johns-hopkins-arthritis/","title":"Vasoactive intestinal peptide (VIP) prevents experimental arthritis","quote":"Mice treated with VIP showed delayed onset, lower incidence and decreased severity of CIA","link_status":"ok","quote_status":"verified"}]},"rationale":"","tokens_in":14899,"tokens_out":2078,"cost":0.02381875,"prev_hash":"genesis","hash":"5c5ceab305c936667a0ef5c1a7ab7a36ad470b94aff2182160db223f8c7430bb"}]}